Bexion has demonstrated that specific versions of these nanovesicles can be used to selectively target a broad range of tumors (both solid and hematologic). Specific formulations have also demonstrated the potential for treatment of a wide range of human cancers, including gliomas, prostate and pancreatic cancer.
Brian Gray, vice president of research of Molecular Targeting Technologies, said: “We will develop dual modality diagnostics using this technology. The ability to visualize the tumor by two imaging modalities offers a new approach for monitoring and accurate resection of tumors.”